Effect of Periodontal Therapy on Crevicular Fluid Interleukin-6 and Interleukin-8 Levels in Chronic Periodontitis

Table 2

Concentration and total amount of IL-6 and IL-8 in GCF as well as PD, CAL, PlI, and GI prior to and following therapy in diseased and nondiseased sites of 12 periodontal patients.

Parameters	Baseline; (Mean ± SD)	6 weeks; (Mean ± SD)	16 weeks; (Mean ± SD)	32 weeks; (Mean ± SD)
IL-6 D	11.38±4.73^∗∗##	33.56±10.54^∗	33.12±12.86^∗	38.72±11.77^∗
IL-6 ND	79.42±34.21^∗∗	82.60±37.52^∗	68.37±18.12^∗	93.63±24.04^∗
TAIL-6 D	1.06±0.41	0.88±0.37	0.79±0.27	1.03±0.27
TAIL-6 ND	1.39±0.56	0.97±0.35	0.99±0.31	1.25±0.39
IL-8 D	1103.76±498.22^∗∗#	2085.27±664.01^∗∗#	3243.4±2271.12	3290.47±609.77
IL-8 ND	3957.32±1983.64^∗∗	5495.88±1985.74^∗∗	4269.38±2607.36	4692.78±1267.21
TAIL-8 D	95.51±40.03^##	59.68±24.78	62.63±17.87	71.32±14.64
TAIL-8 ND	101.97±39.10^##	58.12±19.62	50.16±10.37	54.96±13.06
PD-D	6.10±0.87^∗∗##	3.83±1.16^∗∗	3.46±0.96^∗∗	3.57±1.04^∗∗
PD-ND	2.42±0.58^∗∗	2.17±0.56^∗∗	2.29±0.46^∗∗	2.29±0.55^∗∗
CAL-D	7.35±1.68^∗∗##	5.93±1.92^∗∗	5.57±1.93^∗∗	5.755±1.80^∗∗
CAL-ND	3.42±1.28^∗∗	3.58±1.18^∗∗	3.75±1.11^∗∗	3.58±1.14^∗∗
PlI-D	2.07±0.51^∗∗##	0.71±0.46^∗∗#	0.26±0.44^#	0.57±0.53^∗∗
PlI-ND	1.21±0.41^∗∗##	0.33±0.48^∗∗#	0.08±0.28^#	0.29±0.46^∗∗
GI-D	2.08±0.28^∗∗##	0.67±0.58^∗∗#	0.11±0.32^#	0.44±0.50^∗∗
GI-ND	1.00±0.00^∗∗##	0.17±0.38^∗∗#	0.00±0.00	0.04±0.20^∗∗

D: diseased sites; ND: nondiseased sites; IL-6, IL-8: concentration (pg/𝜇L); TAIL-6, TAIL-8: total amount (pg/30 s).
^∗𝑃<0.05 between diseased and nondiseased sites.
^∗∗𝑃<0.01 between diseased and nondiseased sites.
^#𝑃<0.05 between two examination intervals.
^##𝑃<0.01 between two examination intervals.